메뉴 건너뛰기
Medecine/Sciences
Volumn 25, Issue 12, 2009, Pages 1177-1182
From orthoclone to denosumab, the fast growing market of monoclonal antibodies;D'orthoclone au dénosumab: L'expansion des anticorps monoclonaux à des fins thérapeutiques
Author keywords

[No Author keywords available]
Indexed keywords

EID: 74749090782     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121177     Document Type: Review
Times cited : (5)
References (13)
  • 1
    • 60849128549 scopus 로고    scopus 로고
    • Monoclonal antibodies as innovative therapeutics
    • Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008 ; 9 : 423-30.
    • (2008) Curr Pharm Biotechnol , vol.9 , pp. 423-430
    • Reichert, J.M.1
  • 2
    • 60849117560 scopus 로고    scopus 로고
    • Therapeutic antibodies and derivatives : From the bench to the clinic
    • Beck A, Wurch T, Corvaïa N. Therapeutic antibodies and derivatives : from the bench to the clinic. Curr Pharm Biotechnol 2008 ; 9 : 421-2.
    • (2008) Curr Pharm Biotechnol , vol.9 , pp. 421-422
    • Beck, A.1    Wurch, T.2    Corvaïa, N.3
  • 3
    • 77951583960 scopus 로고    scopus 로고
    • Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009 ; 1 : 1-11.
    • Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. mAbs 2009 ; 1 : 1-11.
  • 4
    • 33846926123 scopus 로고    scopus 로고
    • Trends in the development and approval of monoclonal antibodies for viral infections
    • Reichter J. Trends in the development and approval of monoclonal antibodies for viral infections. BioDrugs 2007 ; 21 : 1-7.
    • (2007) BioDrugs , vol.21 , pp. 1-7
    • Reichter, J.1
  • 5
    • 55749112657 scopus 로고    scopus 로고
    • What's fueling the biotech engine-2007
    • Aggarwal S. What's fueling the biotech engine-2007. Nat Biotechnol 2008 ; 26 : 1227-33.
    • (2008) Nat Biotechnol , vol.26 , pp. 1227-1233
    • Aggarwal, S.1
  • 6
    • 33646228635 scopus 로고    scopus 로고
    • KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    • Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006 ; 66 : 3992-5.
    • (2006) Cancer Res , vol.66 , pp. 3992-3995
    • Lièvre, A.1    Bachet, J.B.2    Le Corre, D.3
  • 7
    • 49449107381 scopus 로고    scopus 로고
    • EGFR inhibitors embrace KRAS
    • Sheridan C. EGFR inhibitors embrace KRAS. Nat Biotechnol 2008 ; 26 : 839-40.
    • (2008) Nat Biotechnol , vol.26 , pp. 839-840
    • Sheridan, C.1
  • 8
    • 33745386921 scopus 로고    scopus 로고
    • Intravitreal avastin : The low cost alternative to lucentis ?
    • Rosenfeld PJ. Intravitreal avastin : the low cost alternative to lucentis ? Am J Ophthalmol 2006 ; 142 : 141-3.
    • (2006) Am J Ophthalmol , vol.142 , pp. 141-143
    • Rosenfeld, P.J.1
  • 9
    • 33749426139 scopus 로고    scopus 로고
    • The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration
    • Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006 ; 355 : 1409-12.
    • (2006) N Engl J Med , vol.355 , pp. 1409-1412
    • Steinbrook, R.1
  • 10
    • 51649086955 scopus 로고    scopus 로고
    • NICE introduces cost sharing scheme for sight drug
    • doi, 10.1136/bmj.al487
    • Dobsan R. NICE introduces cost sharing scheme for sight drug. Br Med J 2008 ; 337 : a1487. doi : 10.1136/bmj.al487.
    • (2008) Br Med J , vol.337
    • Dobsan, R.1
  • 11
    • 51349137409 scopus 로고    scopus 로고
    • Toward biosimilar monoclonal antibodies
    • Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008 ; 26 : 985-90.
    • (2008) Nat Biotechnol , vol.26 , pp. 985-990
    • Schneider, C.K.1    Kalinke, U.2
  • 12
    • 48649110831 scopus 로고    scopus 로고
    • A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein llb/llla receptor blacker (Clotinab) in high-risk patients with percutaneous coronary intervention
    • Moon JY, Kim W, Kim JH, et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein llb/llla receptor blacker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J 2008 ; 49 : 389-99.
    • (2008) Yonsei Med J , vol.49 , pp. 389-399
    • Moon, J.Y.1    Kim, W.2    Kim, J.H.3
  • 13
    • 74749093801 scopus 로고    scopus 로고
    • http://www.emea.europa.eu/pdfs/human/biosimilar/49340805en.pdf

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.